At the European Society of Cardiology (ESC) Congress 2020, positive data has been presented for Eli Lilly and Boehringer Ingelheim’s (BI’s) Jardiance (empagliflozin).
Approximately 55% of type 2 diabetes (T2D) patients suffer from cardiovascular disease (CVD), which often leads to further complications such as major adverse cardiac events (MACEs), including hospitalization from HF, further demonstrating the significance of these results. The EMPEROR-reduced Phase III trial for Jardiance demonstrated risk reduction in hospitalization due to HF for patients with or without T2D. This is highly significant for Jardiance, which could now directly compete with AstraZeneca’s Farxiga (dapagliflozin) for a leading share of the HF market. Farxiga was approved by the FDA in May 2020 for HF in adults with or without T2D. GlobalData expects Jardiance and Farxiga to drive HF market growth and achieve high uptake as cardiologists become increasingly familiar with the SGLT-2I class.
The recent, full-data announcement from Eli Lilly and BI’s EMPEROR-Reduced Phase III trial follows several weeks after the release of top-line data that demonstrated risk reduction in hospitalization for HF with reduced ejection faction (HF-REF). The full data presented at the ESC further demonstrates that, compared to placebo, Jardiance reduces the risk of cardiovascular (CV) hospitalizations by 25% in HF patients with or without T2D over a period of 16 months. Additionally, the average number of total hospitalizations in trial patients was reduced by over 30%, and kidney function improved by 50%, compared to placebo.
If Eli Lilly and BI successfully receive regulatory approval, Jardiance will be a direct competitor to Farxiga and gain a substantial share of the HF market while also strengthening Eli Lilly’s and BI’s presence in the T2D market. However, Eli Lilly and BI are likely to face initial challenges in establishing Jardiance in the HF market due to Farxiga’s head start and cardiologists’ overall unfamiliarity with the SGLT-2I class.